Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

NCT06036836

Conditions
Cutaneous Squamous Cell Carcinoma, Endometrial Cancer, Endometrial Neoplasms, +13 more
Locations
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0643) New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute ( Site 0642) Boston, Massachusetts, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0635) New Brunswick, New Jersey, United States
  • Duke Cancer Institute ( Site 0641) Durham, North Carolina, United States
View all 44 locations
View Trial Details
Completed

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Arizona Oncology Associates, PC- HAL Phoenix, Arizona, United States
  • University of California San Francisco San Francisco, California, United States
  • University of California Los Angeles Santa Monica, California, United States
  • Smilow Cancer Hospital at Yale New Haven New Haven, Connecticut, United States
View all 169 locations
View Trial Details
Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Arizona Oncology Associates, PC- HAL ( Site 8018) Phoenix, Arizona, United States
  • USC Norris Comprehensive Cancer Center ( Site 0038) Los Angeles, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0056) San Francisco, California, United States
  • Sansum Clinic Research ( Site 8014) Santa Barbara, California, United States
View all 251 locations
View Trial Details
Completed

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT04332653

Conditions
Adnexal Diseases, Any Advanced Solid Tumors, Breast Diseases, +41 more
Locations
  • Moffit Cancer Center Tampa, Florida, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine in St. Louis St Louis, Missouri, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details
Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

NCT03221426

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Cancer, +8 more
Locations
  • City of Hope ( Site 0005) Duarte, California, United States
  • Yale Cancer Center ( Site 0016) New Haven, Connecticut, United States
  • Georgetown University ( Site 0015) Washington D.C., District of Columbia, United States
  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0018) Chicago, Illinois, United States
View all 171 locations
View Trial Details
Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

NCT04882241

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Cancer, +8 more
Locations
  • Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638) Bengbu, Anhui, China
  • Beijing Friendship Hospital ( Site 0637) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0221) Beijing, Beijing Municipality, China
  • Fujian Provincial Cancer Hospital ( Site 0230) Fuzhou, Fujian, China
View all 20 locations
View Trial Details
Completed

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT04191135

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • Pacific Cancer Care ( Site 0142) Monterey, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138) San Francisco, California, United States
  • John Wayne Cancer Institute ( Site 0111) Santa Monica, California, United States
  • St. Joseph Heritage Healthcare ( Site 0104) Santa Rosa, California, United States
View all 122 locations
View Trial Details
Completed

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT03675737

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, +6 more
Locations
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0124) Los Angeles, California, United States
  • UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128) Orange, California, United States
  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113) Miami, Florida, United States
  • Greater Baltimore Medical Center ( Site 0102) Baltimore, Maryland, United States
View all 215 locations
View Trial Details
Completed

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, +11 more
Locations
  • HonorHealth Research Institute - Biltmore ( Site 8009) Phoenix, Arizona, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027) Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian ( Site 0038) Newport Beach, California, United States
  • UC Davis Comprehensive Cancer Center ( Site 0017) Sacramento, California, United States
View all 176 locations
View Trial Details

Related conditions